Literature DB >> 19800178

Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.

Tae Hyun Kim1, Hee Jin Chang, Dae Yong Kim, Kyung Hae Jung, Yong Sang Hong, Sun Young Kim, Ji Won Park, Jae Hwan Oh, Seok-Byung Lim, Hyo Seong Choi, Seung-Yong Jeong.   

Abstract

PURPOSE: We retrospectively evaluated the effects of clinical and pathologic factors on disease-free survival (DFS) with the aim of identifying the most discriminating factor predicting DFS in rectal cancer patients treated with preoperative chemoradiotherapy (CRT) and curative resection. METHODS AND MATERIALS: The study involved 420 patients who underwent preoperative CRT and curative resection between August 2001 and October 2006. Gender, age, distance from the anal verge, histologic type, histologic grade, pretreatment carcinoembryonic antigen (CEA) level, cT, cN, cStage, circumferential resection margin, type of surgery, preoperative chemotherapy, adjuvant chemotherapy, ypT, ypN, ypStage, and tumor regression grade (TRG) were analyzed to identify prognostic factors associated with DFS. To compare the discriminatory prognostic ability of four tumor response-related pathologic factors (ypT, ypN, ypStage, and TRG), the Akaike information criteria were calculated.
RESULTS: The 5-year DFS rate was 75.4%. On univariate analysis, distance from the anal verge, histologic type, histologic grade, pretreatment CEA level, cT, circumferential resection margin, type of surgery, preoperative chemotherapeutic regimen, ypT, ypN, ypStage, and TRG were significantly associated with DFS. Multivariate analysis showed that the four parameters ypT, ypN, ypStage, and TRG were, consistently, significant prognostic factors for DFS. The ypN showed the lowest Akaike information criteria value for DFS, followed by ypStage, ypT, and TRG, in that order.
CONCLUSION: In our study, ypT, ypN, ypStage, and TRG were important prognostic factors for DFS, and ypN was the most discriminating factor. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800178     DOI: 10.1016/j.ijrobp.2009.06.019

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  33 in total

1.  Partial pathologic response and nodal status as most significant prognostic factors for advanced rectal cancer treated with preoperative chemoradiotherapy.

Authors:  Marianne Huebner; Bruce G Wolff; Thomas C Smyrk; Jeremiah Aakre; David W Larson
Journal:  World J Surg       Date:  2012-03       Impact factor: 3.352

2.  Oncologic results and prognostic predictors of patients with locally advanced rectal cancer showing ypN0 after radical surgery following neoadjuvant chemoradiotherapy.

Authors:  Kyung-Ha Lee; Jae-Chan Kim; Ji-Yeon Kim; Jin-Su Kim
Journal:  Int J Colorectal Dis       Date:  2015-05-23       Impact factor: 2.571

3.  Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery.

Authors:  Yuji Toiyama; Yasuhiro Inoue; Mikio Kawamura; Aya Kawamoto; Yoshinaga Okugawa; Jyunichiro Hiro; Susumu Saigusa; Koji Tanaka; Yasuhiko Mohri; Masato Kusunoki
Journal:  Int Surg       Date:  2015-02

4.  Less than 12 lymph nodes in the surgical specimen after neoadjuvant chemo-radiotherapy: an indicator of tumor regression in locally advanced rectal cancer?

Authors:  Jaiprakash Gurawalia; Kapil Dev; Sandeep P Nayak; Vishnu Kurpad; Arun Pandey
Journal:  J Gastrointest Oncol       Date:  2016-12

5.  In rectal cancer, the type of desmoplastic response after preoperative chemoradiotherapy is associated with prognosis.

Authors:  Hideki Ueno; Eiji Shinto; Yojiro Hashiguchi; Hideyuki Shimazaki; Yoshiki Kajiwara; Takahiro Sueyama; Junji Yamamoto; Kazuo Hase
Journal:  Virchows Arch       Date:  2015-03-29       Impact factor: 4.064

6.  Tumor regression grades: potential outcome predictor of locally advanced rectal adenocarcinoma after preoperative radiotherapy.

Authors:  Yi-Fan Peng; Wei-Dong Yu; Hong-Da Pan; Lin Wang; Ming Li; Yun-Feng Yao; Jun Zhao; Jin Gu
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

7.  Lymph Node Harvest After Neoadjuvant Treatment for Rectal Cancer and Its Impact on Oncological Outcomes.

Authors:  Rajkumar Billakanti; Ramakrishnan Ayloor Seshadri; Srikanth Soma; Hemanth Makineni; Shirley Sundersingh
Journal:  Indian J Surg Oncol       Date:  2020-07-24

Review 8.  Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain.

Authors:  C Grávalos; P García-Alfonso; R Afonso; V Arrazubi; A Arrivi; J C Cámara; J Capdevila; A Gómez-España; A Lacasta; J L Manzano; M Salgado; J Sastre; E Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

9.  Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?

Authors:  Thilo Sprenger; Hilka Rothe; Klaus Jung; Hans Christiansen; Lena C Conradi; B Michael Ghadimi; Heinz Becker; Torsten Liersch
Journal:  World J Surg Oncol       Date:  2010-04-13       Impact factor: 2.754

10.  [Lymph node dissection after primary surgery and neoadjuvant radiochemotherapy of rectal cancer. Interim analysis of a multicenter prospective observational study (OCUM)].

Authors:  M E Kreis; C A Maurer; R Ruppert; H Ptok; J Strassburg; T Junginger; S Merkel; P Hermanek
Journal:  Chirurg       Date:  2015-12       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.